CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 800 enrolled
Drug / intervention
SilverHawk & TurboHawk Peripheral Plaque Excision Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00883246
NCT00883246N/ACompleted
CompareCT.gov

Determination of Effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the Treatment of Infrainguinal Vessels/Lower Extremities

Medtronic Endovascular·interventional·Posted Apr 17, 2009·Updated Jun 4, 2019

In Brief

A clinical study evaluating SilverHawk & TurboHawk Peripheral Plaque Excision System for Peripheral Arterial Disease and 2 related conditions. Completed, enrolled 800 participants.

Detailed Summary

The purpose of the study is to evaluate the intermediate and long-term effectiveness of stand-alone atherectomy treatment of peripheral arterial disease in the legs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease, Claudication, Critical Limb Ischemia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.2 years ago

Interventions

SilverHawk & TurboHawk Peripheral Plaque Excision Systemdevice

Removal of atherosclerotic plaque from artery walls.